Indegene Ltd

AI
Indegene Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Indegene Ltd

₹ 617 0.70%
04 Nov - close price
indegene.com BSE: 544172 NSE: INDGN
About

Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]

Key Points

Business Overview [1]
The company is a strategic operating partner to the global life sciences industry, supporting commercial, medical, R&D, and safety operations across the product lifecycle. It combines deep life sciences expertise with AI-enabled platforms, data analytics, and governed operating models, servicing the world’s top 20 biopharma companies. Its capabilities span five key areas: Discovery & Evidence, Regulatory & Compliance, Commercial Launch, Content & Engagement, and Patient & Outcomes.

Website BSE NSE
  • Market Cap ₹ 14,872 Cr.
  • Current Price ₹ 617
  • High / Low ₹ 638 / 414
  • Stock P/E 34.9
  • Book Value ₹ 139
  • Dividend Yield 0.36 %
  • ROCE 18.8 %
  • ROE 14.4 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology

Part of BSE 400 MidSmallCap Index BSE 250 SmallCap Index BSE 500 BSE Healthcare Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
636 673 673 676 687 720 756 761 804 942 1,003 1,063 1,122
515 524 534 548 561 589 608 606 664 783 840 889 937
Operating Profit 121 149 139 129 126 132 148 155 141 160 164 174 186
OPM % 19% 22% 21% 19% 18% 18% 20% 20% 17% 17% 16% 16% 17%
12 13 26 22 21 38 26 22 20 19 -10 29 15
Interest 12 12 12 12 4 3 3 4 4 5 7 6 7
Depreciation 20 18 18 20 19 20 21 22 23 40 42 44 46
Profit before tax 101 132 134 120 124 146 149 152 133 135 105 153 147
Tax % 25% 25% 29% 27% 26% 25% 21% 23% 23% 24% 24% 24% 24%
75 99 95 88 92 110 118 116 102 103 80 116 112
EPS in Rs 3.38 4.45 4.26 3.67 3.83 4.58 4.90 4.85 4.25 4.28 3.31 4.82 4.66
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
553 643 966 1,665 2,306 2,590 2,839 3,510 4,131
511 499 736 1,378 1,910 2,084 2,292 2,892 3,448
Operating Profit 42 144 230 287 396 505 548 619 683
OPM % 8% 22% 24% 17% 17% 20% 19% 18% 17%
7 -102 -3 -21 58 79 94 52 54
Interest 6 9 7 6 31 49 22 19 25
Depreciation 17 19 26 33 60 76 80 126 172
Profit before tax 26 14 195 226 363 459 539 525 540
Tax % 45% 191% 23% 28% 27% 27% 25% 24%
14 -12 149 163 266 337 407 401 411
EPS in Rs 0.71 -0.32 7.55 7.44 11.99 15.14 16.95 16.65 17.07
Dividend Payout % 0% 0% 0% 0% 0% 0% 12% 13%
Compounded Sales Growth
10 Years: %
5 Years: 29%
3 Years: 15%
TTM: 36%
Compounded Profit Growth
10 Years: %
5 Years: 23%
3 Years: 16%
TTM: -4%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 14%
Return on Equity
10 Years: %
5 Years: 21%
3 Years: 19%
Last Year: 14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 0.31 0.31 0.31 0.35 44 44 48 48 48
Reserves 73 -105 324 764 1,020 1,385 2,568 3,091 3,310
147 483 51 66 502 490 102 144 157
108 222 220 524 638 627 609 1,337 1,178
Total Liabilities 329 600 596 1,353 2,204 2,546 3,326 4,620 4,693
104 119 86 138 664 646 678 1,812 1,830
CWIP 0 0 0 0 0 0 4 12 0
Investments 0 13 0 120 614 796 1,290 1,100 1,019
225 468 510 1,096 926 1,103 1,355 1,697 1,844
Total Assets 329 600 596 1,353 2,204 2,546 3,326 4,620 4,693

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
65 22 172 297 130 508 442 651
-18 -16 -81 -158 -896 -326 -677 -508
-21 136 -132 233 333 -66 288 -83
Net Cash Flow 25 143 -40 373 -433 115 52 60
Free Cash Flow 48 16 151 272 111 497 412 606
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 196% 34% 96% 128% 60% 125% 110% 129%

Ratios

Consolidated / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 60 127 108 97 102 91 97 102
Inventory Days
Days Payable
Cash Conversion Cycle 60 127 108 97 102 91 97 102
Working Capital Days -7 -5 45 11 41 27 39 5
ROCE % 37% 55% 46% 33% 29% 25% 19%

Insights

In beta
Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Active Client Relationships
Count

Log in to view insights

Please log in to see hidden values.

Login
Total Employees
Count
$1M+ Clients
Count
$25M+ Strategic Clients
Count
Net Revenue Retention
%
Top 20 Customer Revenue
INR Mn
Revenue per Employee
USD

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

5 Recently
Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
3.79% 4.82% 5.03% 5.24% 10.04% 11.30% 11.48% 10.27% 9.92% 12.40%
3.84% 3.17% 3.99% 4.96% 7.20% 6.95% 8.06% 8.29% 8.74% 15.82%
92.38% 92.01% 91.01% 89.80% 82.75% 81.74% 80.44% 81.43% 81.34% 71.76%
No. of Shareholders 2,03,5991,51,4401,53,7891,44,7081,51,9971,51,8091,47,1821,42,1191,38,5331,32,280

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls